https://www.live-feeds.com/feed/iovance-a-top-1-biotech-stock-crashes-in-a-surprise-lung-cancer-twistContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/iovance-a-top-1-biotech-stock-crashes-in-a-surprise-lung-cancer-twisthttps://www.live-feeds.com/feed/iovance-a-top-1-biotech-stock-crashes-in-a-surprise-lung-cancer-twist#u177540Thu, 05 Nov 2026 14:21:31 +0000Iovance Biotherapeutics shares crashed Thursday following updated Phase 2 IOV-LUN-202 trial data for lifileucel in patients with metastatic non-small-cell lung cancer. While the company described the data as positive and consistent with previous results, investors reacted to new durability questions, causing the stock to sink 31% in one instance and trigger its worst day in over 17 months. Baird responded to the data by cutting its price target to $9, leading to a further 11% decline. Some retail investors suggest that selling may not be finished.Why it mattersIovance specializes in Tumor Infi